Capsid Selection And Tissue Targeting Begin Long Before Manufacturing

In this segment of Cell & Gene Live, Solving Vector Yield Challenges in In Vivo CGT, Karen Kozarsky, Ph.D., President and CSO of Vector BioPartners, and Robert Bell, Ph.D., CSO of Ascidian Therapeutics, explain how early biological decisions influence downstream manufacturing success. They discuss capsid selection, tissue targeting, receptor biology, screening models, transgene expression, and why manufacturability should become part of the capsid screening process instead of an afterthought.